# Alternative Splicing Generates Different Parkin Protein Isoforms: Evidences in Human, Rat, and Mouse Brain

Authors: Soraya Scuderi; Valentina La Cognata; Filippo Drago; Sebastiano Cavallaro; Velia D'Agata
Journal: BioMed Research International
 (2014)

---

## Abstract

Parkinson protein 2, E3 ubiquitin protein ligase (PARK2) gene mutations are the most frequent causes of autosomal recessive early onset Parkinson’s disease and juvenile Parkinson disease. Parkin deficiency has also been linked to other human pathologies, for example, sporadic Parkinson disease, Alzheimer disease, autism, and cancer. PARK2 primary transcript undergoes an extensive alternative splicing, which enhances transcriptomic diversification. To date several PARK2 splice variants have been identified; however, the expression and distribution of parkin isoforms have not been deeply investigated yet. Here, the currently known PARK2 gene transcripts and relative predicted encoded proteins in human, rat, and mouse are reviewed. By analyzing the literature, we highlight the existing data showing the presence of multiple parkin isoforms in the brain. Their expression emerges from conflicting results regarding the electrophoretic mobility of the protein, but it is also assumed from discrepant observations on the cellular and tissue distribution of parkin. Although the characterization of each predicted isoforms is complex, since they often diverge only for few amino acids, analysis of their expression patterns in the brain might account for the different pathogenetic effects linked to PARK2 gene mutations.


---

## Body

## 1. Introduction

Homozygous or compound heterozygous mutations of Parkinson protein 2, E3 ubiquitin protein ligase (PARK2) geneare cause (50% of cases) of autosomal recessive forms of PD, usually without atypical clinical features.PARK2 mutations also explain ~15% of the sporadic cases with onset before 45 [1, 2] and act as susceptibility alleles for late-onset forms of Parkinson disease (2% of cases) [3]. Along with Parkinsonism forms,PARK2 gene has been linked to other human pathologies, such as Alzheimer disease [4], autism [5], multiple sclerosis [6], cancer [7, 8], leprosy [9], type 2 diabetes mellitus [10], and myositis [11].PARK2 gene is located in the long arm of chromosome 6 (6q25.2-q27) and spans more than 1.38 Mb [12, 13]. From the cloning of the first human cDNA [12, 13],PARK2genomic organization was thought to include only 12 exons encoding one transcript. Many evidences now demonstrate the existence of additional exonic sequences, which can be alternatively included or skipped in mature mRNAs. To date, dozens ofPARK2 splice transcripts have been described [14] and have been demonstrated to be differentially expressed in tissue and cells [15–21]. These multiplePARK2 splice variants potentially encode for a wide range of distinct protein isoforms with different structures and molecular architectures. However, the characterization and the distribution of these isoforms have not been deeply detailed yet. While studyingPARK2 splice variants mRNAs is relatively simple, differentiating protein isoforms is more complex, since they often diverge only for few amino acids. The complexity of this task could explain the small number of scientific papers on this topic. However, solving this riddle is fundamental to comprehend the precise role ofPARK2 in human diseases. The tissue and cell specific expression pattern ofPARK2isoforms, in fact, might account for the different pathogenetic effects linked to this gene.In this review, we briefly describe the structure ofPARK2 gene, its currently known transcript products, and the predicted encoded protein isoforms expressed in human, rat and mouse; the latter are two commonly used animal models for studying human diseases. Then, we illustrate the expression of these isoforms by recapitulating the major literature evidences already available, which have previously unknowingly demonstrated their existence. We focus on the expression and cellular distribution of parkin isoforms in the brain. Finally, we collect in a panel the differentparkin antibodies, commercially available, which could be useful for the characterization of the isoforms expression and distribution.


## 2.PARK2 Alternative Splice Transcripts Produce Isoforms with Different Structures and Functions

To date, 26 human different cDNAs, corresponding to 21 uniquePARK2alternative splice variants, have been described and are summarized in Figure 1 and Table 1. These mature transcripts are derived from the combination of 17 different exonic regions. Similarly, 20PARK2 transcripts (20 exons) have been characterized in rat (Figure 2 and Table 2) and 9 (15 exons) in mouse (Figure 3 and Table 3). All of them have been carefully described in our previous paper [14]. For each of these variants, the encoded protein isoform, the corresponding molecular weight, and isoelectric point have been predicted and reported in Tables 1, 2, and 3. H8/H17, H9/H13, and H7/H18 isoforms show the same molecular weight and isoelectric point (Table 1), since they have the same amino acid composition; similarly, R2/R7/R14, R17/R18, and R3/R16 show the same primary structure, as shown in Table 2. Although equal, these proteins are encoded by different splice variants which probably produce the same protein with different efficiency.Table 1
Homo sapiens parkin isoforms.
New code identifier
GI
Protein accession number
aa sequence
Predicted MW
pI
H20
469609976
AGH62057.1
530 aa
58,127
6,41
H1
3063387121308969158258616169790968125630744
BAA25751.1BAF43729.1 BAF85279.1 NP_004553.2 ABN46990.1
465 aa
51,65
6,71
H5
284468410169790970
ADB90270.1NP_054642.2
437 aa
48,713
7,12
H10
284468412
ADB90271.1
415 aa
46,412
6,91
H14
284516985
ADB91979.1
387 aa
43,485
7,43
H4
34191069
AAH22014.1
387 aa
42,407
8,15
H8
284468407
*
386 aa
42,52
6,65
H17
284516991
*
386 aa
42,52
6,65
H21
520845529
AGP25366.1
358 aa
39,592
7,08
H6
169790972
NP_054643.2
316 aa
35,63
6,45
H11
284516981
*
274 aa
30,615
6,3
H2
20385797
AAM21457.1
270 aa
30,155
6,05
H3
20385801
AAM21459.1
203 aa
22,192
5,68
H12
284516982
*
172 aa
19,201
6,09
H9
284468408
ADB90269.1
143 aa
15,521
5,54
H13
284516983
ADB91978.1
143 aa
15,521
5,54
H7
194378189
BAG57845.1
139 aa
15,407
6,41
H18
284516993
*
139 aa
15,393
6,41
H15
284516987
ADB91980.1
95 aa
10,531
8,74
H19
469609974
AGH62056.1
61 aa
6,832
10,09
H16
284516989
ADB91981.1
51 aa
5,348
7,79
H1 represents the canonical sequence cloned by Kitada et al., 1998 [12].
* The protein accession number is not present in database.Table 2
Rattus norvegicus parkin isoforms.
New code identifier
GI
Protein accession number
aa sequence
Predicted MW
pI
R13
284810438
ADB96019.1
494 aa
54,829
6,46
R4
20385787
AAM21452.1
489 aa
54,417
6,46
R1
72290967717034 11464986 11527823 7001383
BAA92431.1AAF68666.1 NP_064478.1 AAG37013.1 AAF34874.1
465 aa
51,678
6,59
R5
20385789
AAM21453.1
446 aa
49,367
6,59
R8
20385795284066979
AAM21456.1 ADB77772.1
437 aa
48,734
6,74
R15
520845531
AGP25367.1
421 aa
46,854
6,59
R10
284066981
ADB77773.1
394 aa
43,297
6,06
R19
520845539
AGP25371.1
344 aa
38,558
6,13
R2
18478865
AAL73348.1
274 aa
30,641
6,2
R7
20385793284810436
AAM21455.1ADB96018.1
274 aa
30,641
6,2
R14
520845525520845527
AGP25364.1AGP25365.1
274 aa
30,669
6,2
R12
284468405
ADB90268.1
256 aa
28,006
6,44
R6
20385791
AAM21454.1
203 aa
22,288
5,42
R11
284468403
ADB90267.1
193 aa
21,253
8,54
R9
20385803
AAM21460.1
177 aa
19,84
5,97
R17
520845535
AGP25369.1
139 aa
15,404
6,29
R18
520845537
AGP25370.1
139 aa
15,404
6,29
R3
18478869
AAL73349.1
111 aa
12,329
6,92
R16
520845533
AGP25368.1
111 aa
12,329
6,92
R20
520845541
AGP25372.1
86 aa
9,929
7,5Table 3
Mus musculus parkin isoforms.
New code identifier
GI
Protein accession number
aa sequence
Predicted MW
pI
M1
10179808118131140545692986577675
AAG13890.1NP_057903.1 BAA82404.1 AAI13205.1
464 aa
51,617
6,9
M5
220961631
*
274 aa
30,631
6,54
M2
10179810
AAG13891.1
262 aa
28,7
7,57
M3
10179812
AAG13892.1
255 aa
28,154
8,49
M8
220961637
ACL93283.1
214 aa
23,388
6,51
M7
220961635
ACL93282.1
106 aa
11,482
9,3
M4
74227131
*
75 aa
8,053
8,85
M6
220961633
ACL93281.1
65 aa
7,181
5,62
M9
284829878
ADB99567.1
63 aa
6,967
6,53
*The protein accession number is not present in database.Figure 1
Chromosomal localization, exonic structure of alternative splice variants, and corresponding predicted protein isoforms of humanPARK2. (a) Cytogenetic location of humanPARK2gene (6q26). (b) Exon organization map of the 21 humanPARK2 splice variants currently known. Exons are represented as red bars. The size of introns (black line) is proportional to their length. The codes on left refer to gene identifiers reported in Table 1. (c) Predicted molecular architecture ofPARK2 isoforms. Red boxes represent UBQ domain and blue boxes represent IBR domains.Figure 2
Chromosomal localization, exonic structure of alternative splice variants, and corresponding predicted protein isoforms of ratPARK2. (a) Cytogenetic location of ratPARK2gene (1q11). (b) Exon organization map of the 20 ratPARK2 splice variants currently known. Exons are represented as red bars. The size of introns (black line) is proportional to their length. The codes on left refer to gene identifiers reported in Table 2. (c) Predicted molecular architecture ofPARK2 isoforms. Red boxes represent UBQ domain and blue boxes represent IBR domains.Figure 3
Chromosomal localization, exonic structure of alternative splice variants, and corresponding predicted protein isoforms of mousePARK2. (a) Cytogenetic location of mousePARK2gene (A3.2-A3.3). (b) Exon organization map of the 9 mousePARK2 splice variants currently known. Exons are represented as red bars. The size of introns (black line) is proportional to their length. The codes on left refer to gene identifiers reported in Table 3. (c) Predicted molecular architecture ofPARK2 isoforms. Red boxes represent UBQ domain and blue boxes represent IBR domains.In addition to primary structures, molecular architectures and domains composition have also been evaluated (Figures1, 2, and 3 panels (b) and (c)). As previously described, the original (canonical)PARK2protein (Accession number BAA25751.1) [12] comprises an N-terminal ubiquitin-like (UBQ) domain and two C-terminal in-between ring fingers (IBR) domains. The UBQ domain targets specific protein substrates for proteasome degradation, whereas IBR domains occur between pairs of ring fingers and play a role in protein quality control.PARK2 encoded isoforms structurally diverge from the canonic one for the presence or absence of the UBQ domain and for one of or both IBR domains. Moreover, when the UBQ domain is present, it often differs in length from that of the canonical sequence. Interestingly, some isoforms miss all of these domains.The different molecular architectures and domain composition of isoforms might roughly alter also their functions. Parkin protein acts as an E3 ubiquitin ligase and is responsible of substrates recognition for proteasome-mediated degradation.PARK2 tags various types of proteins, including cytosolic (Synphilin-1, Pael-R, CDCrel-1 and 2a, α-synuclein, p22, and Synaptotagmin XI) [25–29], nuclear (Cyclin E) [15], and mitochondrial ones (MFN1 and MFN2, VDAC, TOM70, TOM40 and TOM20, BAK, MIRO1 and MIRO2, and FIS1) [30–34]. The number of targets is so high that parkin protein results involved in numerous molecular pathways (proteasome-degradation, mitochondrial homeostasis, mitophagy, mitochondrial DNA stability, and regulation of cellular cycle). To date it is unknown if all these functions are mediated by a single protein or by different isoforms. However, considering that parkin mRNAs have a different expression and distribution in tissues and cells [14], which should be also mirrored at the protein level, it is reasonable to hypotisize that these distinct isoforms might perfom specific functions and could be differentially expressed in each cellular phenotype. EachPARK2 splice variants may acts in different manner to suit cell specific needs. This hypothesis is supported by previous evidences showing different and even opposite functions of other splice variants, such as BCl2L12 pattern expression related to cellular phenotype [35]. Finally, based on the extensive alternative splicing process ofPARK2gene, we cannot rule out that additional splice variants with different functions (beyond those listed) may exist.


## 3. Evidences of Multiple Parkin Isoforms in Brain

A remarkable number of papers have demonstrated the existence, in human and other species, of different mRNA parkin variants [15–21]. However, few of them have investigated parkin isoforms existence, and some have done it without the awareness ofPARK2 complex splicing [23, 36, 37]. In fact, although many mRNA parkin splice variants have been cloned, the corresponding proteins have been only deduced through the analysis of the longest open reading frame and uploaded on protein databases as predicted sequences. To date many questions are still unanswered: Are all mRNA parkin splice variants translated? Does a different expression pattern of parkin proteins, in tissue and cells, exist? Does each protein isoform have a specific function? In the following paragraphs we try to answer these questions by summarizing the knowledge accumulated over the last three decades on parkin expression and distribution in human, rat, and mouse brain. Existing data are reinterpreted by considering the complexity level ofPARK2 gene splicing described above.Many conflicting data emerges in the literature regarding the number and relative electrophoretic mobility of parkin proteins. While the majority of papers reported only a band of ~52 kDa corresponding to the canonical parkin isoform, also known asfull length parkin, additional bands (from ~22 kDa to ~100 kDa) both in rodent [23, 28, 36–41] and human brain regions were also detected [22–25, 39, 42–45].Parkin was observed both in rat central and peripheral nervous system. Two major bands of ~50 and ~44 kDa were recognized in cell extracts from ratSubstantia Nigra (SN) and cerebellum by western blot analysis. In adrenal glands there were visualized several immunoreactive bands of 50, 69–66, and 89 kDa [36]. Additional bands were also observed in primary cultures of cortical type I astrocytes [37].Similar result was observed in mouse brain homogenate: a major band of 50 kDa and fainter bands of ~40 and 85/118 kDa were identified on immunoblot. In all these papers, lower and higher molecular weight bands were described as posttranslational modification or proteolytic cleavage of 52 kDa canonical protein or heterodimers resulting from the interaction of parkin with other proteins [42]. However, we speculate that they might correspond to multiple parkin isoforms with different molecular weight.In knocked-out mice for parkin exon 2, several unexpected bands were also observed on immunoblot. This was interpreted as antibody cross-reactivity with nonauthentic parkin protein [46]. However, as shown in Figure 3, these bands might represent isoforms encoded by splice variants not containing the deleted exon (i.e., M5 and M4).Parkin expression was also demonstrated in human brains of normal and sporadic Parkinson disease (PD) subjects, but it was absent in any regions of AR-JP brain [22, 23]. A major band of 52 kDa and a second fainter band of ~41 kDa were observed on immunoblot from human frontal cortex of PD patients and control subjects [22]. Parkin expression was also observed in Lewy bodies (LBs), characteristic neuronal inclusions in PD brain. However, in this regard we highlight widely varying results. Initially, the parkin protein expression was reported in neurons of the SN, locus coeruleus, putamen, and frontal lobe cortex of sporadic PD and control individuals but no parkin-immunoreactivity (IR) was found in SN LBs of PD patients [22, 23]. Later on, parkin-IR was described in nigral LBs of four related human disorders, sporadic PD, α-synuclein-linked PD, LB positive parkin-linked PD, and dementia with LBs (DBL) [24]. These discrepant results might be due to the antibodies used. In fact, as shown in Table 4, aligning the epitope sequence recognized by the antibody to each isoform sequence, we discovered that every antibody identifies a pool of different isoforms.Table 4
Parkin isoforms recognized by antibodies used in some studies.
Name
Target
Recognized Parkin isoforms
M73 (Shimura et al., 1999) [22]
124–137
H1, H4, H5, H8, H9, H10, H13, H14, H17, H20, H21
M74 (Shimura et al., 1999) [22]
293–306
H1, H2, H3, H4, H5, H6, H8, H10, H11, H14, H17, H20, H21
ParkA (Huynh et al., 2000) [23]
96–109
H1, H2, H3, H4, H5, H6, H8, H9, H10, H11, H13, H14, H17, H20, H21
ParkB (Huynh et al., 2000) [23]
440–415
H1, H2, H5, H6, H7, H8, H10, H11, H12, H14, H17, H18, H20, H21
HP6A (Schlossmacher et al., 2002) [24]
6–15
H1, H4, H5, H6, H9, H10, H13, H14, H16, H20
HP7A (Schlossmacher et al., 2002) [24]
51–62
H1, H4, H5, H6, H9, H10, H13, H14, H15, H20
HP1A (Schlossmacher et al., 2002) [24]
84–98
H1, H2, H3, H4, H5, H6, H8, H9, H10, H11, H13, H14, H17, H20, H21
HP2A (Schlossmacher et al., 2002) [24]
342–353
H1, H2, H3, H4, H5, H6, H7, H8, H11, H12, H17, H18, H20, H21
HP5A (Schlossmacher et al., 2002) [24]
453–465
H1, H2, H5, H6, H7, H8, H10, H11, H12, H14, H17, H18, H20, H21In accord with this hypothesis, we also explain discordant results observed by Schlossmacher et al. (2002) regarding the cellular distribution of the protein. In fact, they described strongly labeled cores of classical intracellular LBs in pigmented neurons of the SN in PD and DLB patients by using HP2A antibody, whereas HP1A and HP7A antibodies intensively labeled cytoplasmic parkin, in a granular pattern, of cell bodies and proximal neurites of dopaminergic neurons in both diseased and normal brains [24]. These results might represent a different cellular expression profile of parkin isoforms in healthy and diseased human brains.This hypothesis is supported by another study demonstrating a different expression profile of parkin mRNA splice variants in frontal cortex of patients with common dementia with LB, pure form of dementia with LB, and Alzheimer disease suggesting the direct involvement of isoform-expression deregulation in the development of such neurodegenerative disorders [17]. To date there exists only one paper that has dealt with parkin amino acid sequencing [47]. Trying to ensure that the signal observed on human serum by western blot analysis belongs to parkin protein, they cut off the area on the blot between 50 and 55 kDa in two separate pieces and performed a MALDI-TOF analysis on each. Peptides peaks analysis revealed the presence of six other proteins with similar sequence to canonical one. However, authors did not even speculate that they could represent additional parkin isoforms.Further evidences on the existence of multiple isoforms come from the conflicting data on their tissue and cellular distribution. Parkin protein is particularly abundant in the mammalian brain and retina [22, 23, 36, 48, 49]. In human, parkin immunoreactivity (IR) has been observed in SN, locus coeruleus, putamen, and frontal lobe cortex [22, 23]. Similarly, it has been strongly measured in rat hippocampus, amygdaloid nucleus, endopiriform nucleus, cerebral cortex, colliculus, and SN (pars compacta and pars reticulata) [37, 50].Analog parkin distribution was reported in mouse. Most immunoreactive cells were found in the hindbrain. In the cerebellum only the cells within the cerebellar nuclei were positive, while the structures located in the mesencephalon presented moderate to strong immunopositivity. In the ventral part of the mesencephalon the red nucleus showed large strongly stained cells. In the SN moderate parkin immunoreactivity was confined to the pars reticulate. In the dorsal mesencephalon, immunopositive cells were found in the intermediate and deep gray layer of the superior colliculus and in all parts of the inferior colliculus [12, 36, 41, 51].Although in most brain regions good correlations between parkin-IR and mRNA were observed, incongruent data emerged from some paper in rat SNc (substantia nigra pars compacta), hippocampus, and cerebellar Purkinje cells distribution, where mRNA was detected but no parkin-IR was revealed [23, 36].Furthermore, in an early study, parkin was described in cytoplasm, in granular structure, and in neuronal processes but was absent in the nucleus [22]. Subsequently other studies reported also its nuclear localization [23, 37, 48, 52–54]. Finally, some papers have also observed a small mitochondrial pool of the protein [55, 56]. All these evidences have suggested that protein could localize to specific subcellular structure under some circumstances. However, it is also reasonably hypothesized that a specific pattern of subcellular distribution of parkin isoforms is related to each cellular phenotype, since in all these papers, protein immunolocalization was performed by using antibodies recognizing different epitopes. Some discrepancies are also observed in the expression of parkin in the SNc of patients affected by other forms of parkinsonism [23].Brain isoforms might have different species-specific biochemical characteristics, when comparing murine versus human parkin. In fact, it has been shown that mouse protein is easily extracted from brain by high salt buffer, instead human parkin is only extracted with harsher buffers, especially in elderly. This suggested that human parkin becomes modified or interacts with other molecules with age, and this alters its biochemical properties [42]. However, we cannot rule out that this may correlate to a specific expression pattern of isoforms with different biochemical properties in the brains of rodents and humans relative to age.All of these observations were also supported by contradictory results emerging from clinical studies. Initially, recessive mutations in the parkin gene were related to sporadic early onset parkinsonism [2]; however, the mode of transmission was subsequently rejected by other genetic studies with not only homozygous or compound heterozygous mutations, but also single heterozygous mutations, affecting only one allele of the gene [2, 57–61]. It has been suggested that haploinsufficiency is a risk factor for disease, but certain mutations are dominant, conferring dominant-negative or toxic gain of functions of parkin protein [61]. However, in light of the evidence outlined above, it is possible that some single heterozygous mutation might affect gene expression by inducing loss of function of some isoforms and gain of function of other.


## 4. The Diversified Panel of Antibodies Commercially Available againstPARK2

To date more than 160PARK2 antibodies are commercially available. They are obtained from different species (generally rabbit or mouse) and commercialized by various companies. Table 5 lists 32 commercially availablePARK2 antibodies whose immunogens used are specified by providers in datasheet. Some of them recognize a common epitope, therefore, have been included in the same group. Tables 6, 7, and 8 report, respectively, human, rat, and mouse parkin isoforms recognized by these antibodies. When the amino acid sequence recognized by the antibody perfectly match with the sequence of the protein, it is very likely to get a signal by western blot or immunohistochemistry analysis (this is indicated in the table by “Yes”). Instead, if the antibody recognizes at least 8 consecutive amino acids on the protein, it is likely to visualize a signal both by western blot or immunohistochemistry analysis (this is indicated in the table by “May be”). Finally, if the antibody recognizes less than 8 consecutive amino acids, it could rule out the possibility to visualize a signal on immunoblot or immunohistochemistry analysis (this is indicated in the table by “No”). The use of these 32 antibodies may allow the identification of at least 15 differentPARK2 epitopes (Table 5). Although no epitope is isoform specific, the combinatorial use of antibodies targeting different protein regions may provide a precious aid to decode the exact spectrum ofPARK2 isoforms expressed in tissues and cells. An example of combinatorial use of antibodies has been reported in Figure 4. On rat brain homogenate, these five antibodies raised against different parkin epitopes, revealed the canonical ~50 kDa band, but additional putative bands of higher and lower molecular weight were visualized. This experimental data reinforce the existence of more than one parkin isoform and confirm that the investigation of parkin expression profile should not be restricted to the use of a single antibody. The latter approach, in fact, could not reveal the entire spectrum of parkin variants.Table 5
List of antibodies targetingPARK2 isoforms.
Antibody group #
Generic name
Target domain
Trade name
Companies
#1
H00005071-B01P
Abnova
1 aa–387 aa
H00005071-D01P
Abnova
H00005071-D01
Abnova
#2
OASA06385
Aviva System biology
83 aa–97 aa
AHP495
AbD Serotec
MD-19-0144
Raybiotech, Inc.
DS-PB-01562
Raybiotech, Inc.
PAB14022
Abnova
#3
MCA3315Z
AbD Serotec
288 aa–388 aa
H00005071-M01
Abnova
#4
PAB1105
Abnova
62 aa–80 aa
70R-PR059
Fitzgerald
#5
PAB0714
Abnova
305 aa–323 aa
AB5112
Millipore Chemicon
R-113-100
Novus biologicals
#6
P5748
Sigma
298 aa–313 aa
GTX25667Parkin antibody CR20121213_GTX25667
GeneTex InternationalCorporation
ABIN122870
Antibodies on-line
PA1-751
Thermo FisherScientific, Inc.
#7
R-114-100
Novus biologicals
295 aa–311 aa
Anti-Parkin, aa295-311 hParkin; C-terminal
Millipore Chemicon
#8
MAB5512
Millipore Chemicon
399 aa–465 aa
Anti-Parkin antibody,clone PRK8/05882
Millipore Upstate
Parkin (PRK8): sc-32282
Santa Cruz
#9
Parkin (H-300): sc-30130
Santa Cruz
61 aa–360 aa
Parkin (D-1): sc-133167
Santa Cruz
Parkin (H-8): sc-136989
Santa Cruz
#10
EB07439
Everest Biotech
394 aa–409 aa
GTX89242PARK2
antibody, internal CR20121213_GTX89242
GeneTex InternationalCorporation
NB100-53798
Novus biologicals
#11
GTX113239 Parkinantibody [N1C1] CR20121213_GTX113239
GeneTex International Corporation
28 aa–258 aa
#12
10R-3061
Fitzgerald
390 aa–406 aa
#13
A01250-40
GenScript
300 aa–350 aa
#14
NB600-1540
Novus biologicals
399 aa–412 aa
#15
ARP43038_P050
Aviva System biology
311 aa–360 aa
Antibodies against canonicalPARK2 isoform (NP_004553.2) were grouped if they recognize the same epitope. To each group was assigned a new identification code (#).Table 6
Homo sapiens.
New code identifier
Ab #1
Ab #2
Ab #3
Ab #4
Ab #5
Ab #6
Ab #7
Ab #8
Ab #9
Ab #10
Ab #11
Ab #12
Ab #13
Ab #14
Ab #15
H20
May be (360 aa)
Yes
May be (64 aa)
Yes
Yes
Yes
Yes
Yes
May be (299 aa)
May be (17 aa)
May be (230 aa)
Yes
Yes
Yes
May be (47 aa)
H1
May be (360 aa)
Yes
May be (64 aa)
Yes
Yes
Yes
Yes
Yes
Yes
May be (17 aa)
Yes
Yes
Yes
Yes
May be (47 aa)
H5
May be (333 aa)
Yes
May be (64 aa)
Yes
Yes
Yes
Yes
Yes
May be (271 aa)
May be (17 aa)
May be (202 aa)
Yes
Yes
Yes
May be (47 aa)
H10
May be (311 aa)
Yes
May be (22 aa)
Yes
No
May be (14 aa)
Yes
Yes
May be (250 aa)
May be (17 aa)
May be (230 aa)
Yes
No
Yes
No
H14
May be (283 aa)
Yes
May be (22 aa)
Yes
No
May be (14 aa)
Yes
Yes
May be (222 aa)
May be (17 aa)
yes (partial match 202 aa/231 aa)
Yes
May be (12 aa)
May be (15 aa)
No
H4
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No
May be (299 aa)
No
May be (230 aa)
No
Yes
No
May be (47 aa)
H8
May be (274 aa)
Yes
May be (64 aa)
No
Yes
Yes
Yes
Yes
May be (281 aa)
May be (17 aa)
May be (178 aa)
Yes
Yes
May be (15 aa)
May be (47 aa)
H17
May be (274 aa)
Yes
May be (64 aa)
No
Yes
Yes
Yes
Yes
May be (280 aa)
May be (17 aa)
May be (178 aa)
Yes
Yes
May be (15 aa)
May be (47 aa)
H21
May be (254 aa)
Yes
May be (64 aa)
No
Yes
Yes
Yes
Yes
May be (252 aa)
May be (17 aa)
May be (150 aa)
Yes
Yes
May be (15 aa)
May be (47 aa)
H6
May be (148 aa)
No
May be (64 aa)
No
Yes
Yes
Yes
Yes
Yes
Yes
May be (52 aa)
Yes
Yes
Yes
Yes
H11
May be (162 aa)
No
May be (64 aa)
No
Yes
Yes
Yes
Yes
Yes
Yes
May be (66 aa)
Yes
Yes
Yes
Yes
H2
May be (161 aa)
No
May be (64 aa)
No
Yes
Yes
Yes
Yes
Yes
Yes
May be (67 aa)
Yes
Yes
Yes
Yes
H3
May be (161 aa)
No
May be (64 aa)
No
Yes
Yes
Yes
No
Yes
No
May be (67 aa)
No
Yes
No
Yes
H12
May be (42 aa)
No
May be (42 aa)
No
May be (12 aa)
No
No
Yes
Yes
Yes
No
Yes
May be (39 aa)
Yes
Yes
H9
May be (137 aa)
Yes
No
Yes
No
No
No
No
Yes
No
May be (110 aa)
No
No
No
No
H13
May be (137 aa)
Yes
No
Yes
No
No
No
No
Yes
No
May be (110 aa)
No
No
No
No
H7
May be (27 aa)
No
May be (27 aa)
No
No
No
No
Yes
May be (30 aa)
Yes
No
Yes
May be (24 aa)
Yes
Yes
H18
May be (27 aa)
No
May be (27 aa)
No
No
No
No
Yes
May be (30 aa)
Yes
No
Yes
May be (24 aa)
Yes
Yes
H15
May be (65 aa)
No
No
No
No
No
No
No
No
No
May be (38 aa)
No
No
No
No
H19
No
No
No
No
No
No
No
Yes
No
No
No
No
No
No
No
H16
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Yes = perfect match between predicted protein sequence and antibody epitope.
May be = partial match between predicted protein sequence and antibody epitope; in parenthesis number of amino acid matching/total number of amino acid recognized by antibody epitope.
No = matching between predicted protein sequence and antibody epitope is less than 8 consecutive amino acids.Table 7
Rattus norvegicus.
New code identifier
Ab #1
Ab #2
Ab #3
Ab #4
Ab #5
Ab #6
Ab #7
Ab #8
Ab #9
Ab #10
Ab #11
Ab #12
Ab #13
Ab #14
Ab #15
R13
May be (306 aa)
May be (5 aa)
May be (69 aa)
May be (14 aa)
Yes
Yes
Yes
May be (66 aa)
May be (248 aa)
May be (14 aa)
May be (180 aa)
May be (15 aa)
May be (48 aa)
May be (13 aa)
May be (48 aa)
R4
May be (307 aa)
May be (5 aa)
May be (69 aa)
May be (14 aa)
Yes
Yes
Yes
May be (66 aa)
May be (247 aa)
May be (14 aa)
May be (179 aa)
May be (15 aa)
May be (48 aa)
May be (13 aa)
May be (49 aa)
R1
May be (307 aa)
May be (5 aa)
May be (70 aa)
May be (14 aa)
Yes
Yes
Yes
May be (66 aa)
May be (249 aa)
May be (14 aa)
May be (180 aa)
May be (15 aa)
May be (49 aa)
May be (13 aa)
May be (49 aa)
R5
May be (305 aa)
May be (5 aa)
May be (69 aa)
May be (14 aa)
Yes
Yes
Yes
May be (31 aa)
May be (247 aa)
May be (14 aa)
May be (179 aa)
May be (15 aa)
May be (48 aa)
May be (13 aa)
May be (48 aa)
R8
May be (279 aa)
May be (5 aa)
May be (69 aa)
May be (14 aa)
Yes
Yes
Yes
May be (66 aa)
May be (221 aa)
May be (14 aa)
May be (153 aa)
May be (15 aa)
May be (48 aa)
May be (13 aa)
May be (48 aa)
R15
May be (254 aa)
May be (5 aa)
May be (73 aa)
May be (14 aa)
Yes
Yes
Yes
May be (66 aa)
May be (248 aa)
May be (14 aa)
May be (153 aa)
May be (15 aa)
May be (49 aa)
May be (13 aa)
May be (49 aa)
R10
May be (173 aa)
May be (5 aa)
May be (69 aa)
May be (14 aa)
Yes
Yes
Yes
May be (9 aa)
May be (248 aa)
No
May be (180 aa)
No
May be (48 aa)
No
May be (48 aa)
R19
May be (162 aa)
No
May be (70 aa)
No
Yes
Yes
Yes
May be (68 aa)
May be (173 aa)
May be (14 aa)
May be (74 aa)
May be (15 aa)
May be (49 aa)
May be (13 aa)
May be (49 aa)
R2
May be (147 aa)
No
May be (72 aa)
No
Yes
Yes
Yes
May be (68 aa)
May be (156 aa)
May be (14 aa)
May be (55 aa)
May be (15 aa)
May be (48 aa)
May be (13 aa)
May be (48 aa)
R7
May be (147 aa)
No
May be (72 aa)
No
Yes
Yes
Yes
May be (68 aa)
May be (153 aa)
May be (14 aa)
May be (55 aa)
May be (15 aa)
May be (48 aa)
May be (13 aa)
May be (49 aa)
R14
May be (149 aa)
No
May be (73 aa)
No
Yes
Yes
Yes
May be (68 aa)
May be (155 aa)
May be (14 aa)
May be (56 aa)
May be (15 aa)
May be (49 aa)
May be (13 aa)
May be (49 aa)
R12
May be (196 aa)
May be (5 aa)
No
May be (14 aa)
No
No
No
May be (9 aa)
May be (138 aa)
No
May be (168 aa)
No
No
No
No
R6
May be (147 aa)
No
May be (69 aa)
No
Yes
Yes
Yes
No
May be (153 aa)
No
May be (55 aa)
No
May be (48 aa)
No
May be (48 aa)
R11
May be (139 aa)
May be (5 aa)
No
May be (14 aa)
No
No
No
No
May be (82 aa)
No
May be (112 aa)
No
No
No
No
R9
May be (60 aa)
No
May be (68 aa)
No
Yes
Yes
Yes
May be (68 aa)
May be (67 aa)
May be (14 aa)
No
May be (15 aa)
May be (48 aa)
May be (13 aa)
May be (48 aa)
R17
May be (25 aa)
No
May be (33 aa)
No
No
No
No
May be (68 aa)
May be (32 aa)
May be (14 aa)
No
May be (15 aa)
May be (22 aa)
May be (13 aa)
May be (35 aa)
R18
May be (25 aa)
No
May be (33 aa)
No
No
No
No
May be (68 aa)
May be (32 aa)
May be (14 aa)
No
May be (15 aa)
May be (22 aa)
May be (13 aa)
May be (35 aa)
R3
May be (87 aa)
No
No
No
No
No
No
May be (8 aa)
May be (86 aa)
No
May be (55 aa)
No
No
No
No
R16
May be (87 aa)
No
No
No
No
No
No
May be (8 aa)
May be (86 aa)
No
May be (55 aa)
No
No
No
No
R20
No
No
No
No
No
No
No
May be (66 aa)
No
May be (14 aa)
No
May be (15 aa)
No
May be (13 aa)
No
Yes = perfect match between predicted protein sequence and antibody epitope.
May be = partial match between predicted protein sequence and antibody epitope; in parenthesis number of amino acid matching/total number of amino acid recognized by antibody epitope.
No = matching between predicted protein sequence and antibody epitope is less than 8 consecutive amino acids.Table 8
Mus musculus.
New code identifier
Ab #1
Ab #2
Ab #3
Ab #4
Ab #5
Ab #6
Ab #7
Ab #8
Ab #9
Ab #10
Ab #11
Ab #12
Ab #13
Ab #14
Ab #15
M1
May be (294 aa)
No
May be (61 aa)
May be (13 aa)
May be (18 aa)
Yes
Yes
May be (70 aa)
May be (244 aa)
No
May be (176 aa)
May be (15 aa)
May be (48 aa)
May be (14 aa)
Yes
M5
May be (147 aa)
No
May be (62 aa)
No
May be (18 aa)
Yes
Yes
May be (70 aa)
May be (153 aa)
No
May be (55 aa)
May be (15 aa)
May be (48 aa)
May be (14 aa)
Yes
M2
May be (191 aa)
No
No
May be (13 aa)
No
No
No
No
May be (134 aa)
No
May be (164 aa)
No
No
No
No
M3
May be (192 aa)
No
No
May be (13 aa)
No
No
No
No
May be (135 aa)
No
May be (165 aa)
No
No
No
No
M8
May be (161 aa)
No
No
May be (13 aa)
No
No
No
No
May be (106 aa)
No
May be (136 aa)
No
No
No
No
M7
May be (53 aa)
No
No
No
No
No
No
No
No
No
May be (27 aa)
No
No
No
No
M4
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
M6
May be (53 aa)
No
No
No
No
No
No
No
No
No
May be (27 aa)
No
No
No
No
M9
May be (53 aa)
No
No
No
No
No
No
No
No
No
May be (27 aa)
No
No
No
No
Yes = perfect match between predicted protein sequence and antibody epitope.
May be = partial match between predicted protein sequence and antibody epitope; in parenthesis number of amino acid matching/total number of amino acid recognized by antibody epitope.
No = matching between predicted protein sequence and antibody epitope is less than 8 consecutive amino acids.Differential detection of parkin isoforms in rat brain using five anti-parkin antibodies. (a) Representative immunoblot of parkin isoforms in rat brain visualized by using five different antibodies. Ab1, Ab2, Ab3, Ab4, and Ab5 correspond to groups #3, #4, #5, #8, and #9 of Table5. Immunoblot for β-tubulin was used as loading control. (b) Canonical parkin sequence domains recognized by the five antibodies.
(a)
(b)


## 5. Conclusion

Alternative splicing is a complex molecular mechanism that increases the functional diversity without the need for gene duplication. Alternative splicing performs a crucial regulatory role by altering the localization, function, and expression level of gene products, often in response to the activities of key signaling pathways [62].PARK2 gene, as the vast majority of multiexon genes in humans, undergoes alternative splicing [14, 63, 64]. The importance of alternative splicing in the regulation of diverse biological processes is highlighted by the growing list of human diseases associated with known or suspected splicing defects, including PD [65].Mutations that affectPARK2 splicing could modify the levels of correctly spliced transcripts, alter their localization, and lead to a loss of function of some of them and/or gain of function of others in time- and cell-specific manner. Even if few, some evidences supporting this hypothesis have been already described. Preliminary studies reportedPARK2 isoforms with defective degradation activity of cyclin E and control of cellular cycle [15] or characterized by altered solubility and intracellular localization [66]. No evidence of gain of function has been reported, but it is plausible, because a functional screen of thePARK2 splice variants has not been done yet. The huge number of molecular targets attributed to full-size parkin protein could be shared by the others parkin isoforms which could have additional biological activities that until now are uncosidered. In light of this consideration, alteration of the natural splicing ofPARK2 and deregulation in the expression of parkin isoforms might lead to the selective degeneration of dopaminergic neurons in SN of ARJP. However this is a hypothesis, since the functional screen of thePARK2 splice variants is not available and this field is still unexplored.All these could, at least in part, justifying the conflicting and heterogeneous data of studies revised in this work, which preceded the knowledge ofPARK2alternative splicing and expression of multiple isoforms for this gene. UnderstandingPARK2alternative splicing could open up new scenarios for the resolution of some Parkinsonian syndrome.



---

*Source: 690796-2014-07-16.xml*